Introduction {#s1}
============

Uromodulin, also known as Tamm-Horsfall protein, is a 105 kDa glycoprotein exclusively expressed in the kidney by epithelial cells lining the thick ascending limb (TAL) of Henle's loop. It is a glycosylphosphatidylinositol (GPI)-anchored protein mainly localised at the apical plasma membrane of TAL epithelial cells. Uromodulin is secreted into the renal tubule through a conserved proteolytic cleavage ([@bib48]). In the urine it constitutes the most abundant protein under physiological conditions ([@bib52]) and it is mainly found as high molecular-weight polymers. Uromodulin polymerisation is mediated by its Zona Pellucida (ZP) domain, a module present in several proteins that assemble into extracellular polymers, such as components of the egg coat (including sperm receptors ZP3 and ZP2) and of the inner ear tectorial membrane ([@bib27]). Specific cleavage is necessary for protein assembly into polymers, as it releases an inhibitory hydrophobic motif (external hydrophobic patch, EHP) distal to the ZP domain that prevents polymerisation ([@bib26]; [@bib49]; [@bib19]).

The biological function of uromodulin is complex and only partly understood. Studies in *Umod*^-/-^ mice demonstrated that it protects against urinary tract infections ([@bib3]) and renal stone formation ([@bib33]). Uromodulin has also been shown to modulate the activity of innate immunity cells via Toll-like receptor 4 signalling ([@bib56]) or via activation of the inflammasome ([@bib11]) and to regulate granulopoiesis and systemic neutrophil homeostasis ([@bib37]). Finally, it is involved in the regulation of NaCl transport in the TAL, based on its role in promoting surface expression of the renal outer medullary potassium channel (ROMK2) ([@bib45]) and of the sodium-potassium-chloride co-transporter (NKCC2) ([@bib38]).

Recent data showed that uromodulin plays an important role in chronic diseases of the kidney ([@bib43]). Mutations in the uromodulin gene (*UMOD*) cause an autosomal dominant tubulo-interstitial kidney disease ([@bib20]). In addition, genome-wide association studies demonstrated that common variants in the *UMOD* gene are associated with increased risk for chronic kidney disease (CKD) and hypertension ([@bib30]; [@bib19]). Such an effect is due to higher *UMOD* expression driven by the presence of risk alleles in its gene promoter ([@bib58]).

Given the importance of polymerisation for uromodulin activity and the fact that this process depends on a specific protein cleavage, in this work we aimed at identifying the protease responsible for such cleavage and urinary secretion.

Results {#s2}
=======

Uromodulin cleavage and polymerisation in MDCK cells is mediated by a serine protease {#s2-1}
-------------------------------------------------------------------------------------

As for other ZP proteins, uromodulin cleavage at a specific site in the protein C-terminus releases the interaction between two hydrophobic motifs (internal hydrophobic patch, IHP; external hydrophobic patch, EHP) ([Figure 1A](#fig1){ref-type="fig"}), leading to conformational activation of the ZP domain and protein polymerisation ([@bib26]; [@bib49]; [@bib19]).10.7554/eLife.08887.003Figure 1.MDCK cells as a model to study physiological uromodulin shedding.(**A**) Schematic representation of human uromodulin domain structure containing a leader peptide (predicted to be cleaved at residue 23), three EGF-like domains, a central domain with 8 conserved cysteines (D8C), a bipartite Zona Pellucida (ZP) domain (ZP-N/ZP-C) and a glycosylphosphatidylinositol (GPI)-anchoring site (predicted at position 614). Internal (IHP) and External (EHP) Hydrophobic Patches ([@bib26]; [@bib49]), Consensus Cleavage Site (CCS) and seven N-glycosylation sites (Ψ) are also indicated. (**B**) Immunofluorescence analysis of non-permeabilised MDCK cells expressing uromodulin. Polymers formed by the protein are clearly detected on the cell surface. Scale bar, 50 µm. (**C**) Electron microscopy analysis of uromodulin polymers purified from the medium of MDCK cells. The arrows indicate the typical protrusions of uromodulin filaments spaced about 130 Å. Scale bar, 100 nm. (**D**) Representative Western blot analysis of N-deglycosylated uromodulin secreted by transfected MDCK cells or purified from urine. A single isoform is clearly seen in the urinary sample. An isoform with similar molecular weight is released by MDCK cells (white arrowhead), which also secrete a longer and more abundant one (black arrowhead). (**E**) Representative tandem mass-spectrometry (MS/MS) spectrum confirming the identity of the C-terminal peptide ^572^DTMNEKCKPTCSGTRF^587^ of the short uromodulin isoform released by MDCK cells and table of fragmented ions. The C-terminal residue F587 is identical to the one that we mapped in human urinary protein ([@bib48]).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.003](10.7554/eLife.08887.003)

To understand the nature of such cleavage, we took advantage of a cellular system, Madin-Darby Canine Kidney (MDCK) cells, where transfected human uromodulin assembles extracellularly in filamentous polymers ([Figure 1B,C](#fig1){ref-type="fig"}) that are indistinguishable from the urinary ones ([@bib25]). In these cells, uromodulin is secreted as two isoforms that can be separated on gel electrophoresis after enzymatic removal of protein N-glycans at about 72 and 77 kDa ([Figure 1D](#fig1){ref-type="fig"}). Only the shorter isoform assembles into polymers, since it is generated by a cleavage that releases the inhibitory EHP motif, while the longer one is generated by a more distal cleavage and still retains the EHP ([@bib49]). The short uromodulin isoform released by MDCK cells corresponds to the one found in the urine, as it shares the same molecular weight ([Figure 1D](#fig1){ref-type="fig"}) and the same C-terminal residue (F587 \[[@bib48]\]) ([Figure 1E](#fig1){ref-type="fig"}), demonstrating that uromodulin undergoes physiological cleavage in these cells.

As mapping of the C-terminus of the short uromodulin isoform suggests proteolytic cleavage, we first treated uromodulin-expressing MDCK cells with a protease inhibitor cocktail (PIC). This treatment led to significant reduction of uromodulin polymerisation on the surface of the cells ([Figure 2A](#fig2){ref-type="fig"}) that is not due to any alteration of protein expression or intracellular distribution ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), confirming that the polymerisation-competent uromodulin isoform is generated through the action of a protease. We then treated MDCK cells with the single PIC components, each targeting a specific catalytic type of protease, and observed that only inhibitors of serine proteases significantly reduced uromodulin polymerisation ([Figure 2A](#fig2){ref-type="fig"}). Consistently, the expression of the Kunitz-type serine protease inhibitor Hepatocyte growth factor Activator Inhibitor-1 (HAI-1) ([@bib55]) essentially abolished uromodulin polymerisation on the surface of MDCK cells and reduced the secretion of the shorter uromodulin isoform ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). To explore the role of membrane-association for uromodulin cleavage, we expressed a soluble isoform of uromodulin, generated by truncation at the GPI-anchoring site (S614X), that is efficiently trafficked and secreted in MDCK cells ([@bib49]). Interestingly, this isoform was neither processed to the shorter variant nor it formed polymers ([Figure 2B,C](#fig2){ref-type="fig"}), indicating that, as in the case of ZP3 ([@bib25]), membrane association is necessary to allow uromodulin physiological cleavage and polymerisation. From these results we conclude that physiological cleavage of uromodulin depends on a serine protease, and that this enzyme is likely membrane associated.10.7554/eLife.08887.004Figure 2.A serine protease is responsible for the release of polymerisation-competent uromodulin.(**A**) Immunofluorescence analysis showing uromodulin on the surface of MDCK cells treated with vehicle (DMSO) (ctr), protease inhibitor cocktail (PIC) or single PIC components, as indicated. Scale bar, 50 µm. Quantification of the average surface of uromodulin polymers shows that only treatment with PIC or with specific serine protease inhibitors (AEBSF, aprotinin and leupeptin) significantly reduces uromodulin polymerisation on the surface of MDCK cells. Bars indicate average ± s.e.m. \*\*\*p\<0.001 (Mann-Whitney test). The graph represents mean ratios of 3 independent experiments ([Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}). (**B**) Immunofluorescence analysis of permeabilised (left) or non-permeabilised (right) MDCK cells expressing soluble uromodulin mutant S614X. Uromodulin polymerisation is abolished by preventing its association to the membrane. Scale bar, 50 µm. (**C**) Representative Western blot analysis of N-deglycosylated uromodulin secreted by MDCK cells expressing wild-type or soluble (S614X) uromodulin. Lack of plasma membrane anchoring does not affect uromodulin secretion but it abolishes its cleavage at the physiological site (white arrowhead).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.004](10.7554/eLife.08887.004)10.7554/eLife.08887.005Figure 2---source data 1.Quantification of the area of uromodulin polymers on the surface of MDCK cells after protease inhibitor treatment ([Figure 2A](#fig2){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.005](10.7554/eLife.08887.005)10.7554/eLife.08887.006Figure 2---source data 2.Short cleavage inhibition by HAI-1 expression ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.006](10.7554/eLife.08887.006)10.7554/eLife.08887.007Figure 2---figure supplement 1.PIC treatment does not affect uromodulin intracellular distribution and expression.(**A**) Immunofluorescence analysis showing intracellular distribution of uromodulin in MDCK cells treated with vehicle (DMSO) (ctr) or protease inhibitor cocktail (PIC). KDEL is a marker of the endoplasmic reticulum (ER). Scale bar, 16 µm. (**B**) Representative Western blot analysis of uromodulin in lysates of MDCK cells under the same conditions as above. The upper band corresponds to the mature, fully glycosylated protein, the lower band corresponds to the immature protein carrying ER-type glycosylation (Schaeffer et al., 2012). Alpha-tubulin is shown as a loading control. PIC treatment does not alter uromodulin intracellular distribution nor its expression.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.007](10.7554/eLife.08887.007)10.7554/eLife.08887.008Figure 2---figure supplement 2.Expression of the serine protease inhibitor HAI-1 effectively reduces uromodulin cleavage at the urinary site.(**A**) Immunofluorescence analysis showing uromodulin on the surface of MDCK cells co-expressing the serine protease inhibitor HAI-1 (Hepatocyte growth factor Activator Inhibitor-1), as indicated. HAI-1 expression essentially abolishes uromodulin polymerisation on the cell surface. Scale bar, 50 µm. (**B**) Representative Western blot analysis showing uromodulin and HAI-1 expression in cell lysates of transfected MDCK cells, as indicated. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) is shown as a loading control. (**C**) Representative Western blot analysis of N-deglycosylated uromodulin secreted by MDCK cells co-expressing HAI-1, as indicated. Densitometric analysis (average ± s.d. of 3 independent experiments, [Figure 2---source data 2](#SD2-data){ref-type="supplementary-material"}) shows the ratio between the short and the long uromodulin isoforms in the absence or presence of HAI-1 co-expression, as indicated. The serine protease inhibitor HAI-1 strongly reduces the amount of the short uromodulin isoform released in the culturing medium by MDCK cells. \*p\<0.05 (Student's *t* test).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.008](10.7554/eLife.08887.008)

Identification of hepsin as the protease cleaving uromodulin *in vitro* {#s2-2}
-----------------------------------------------------------------------

We moved further starting from the interesting observation that uromodulin expressed in a different kidney-derived cell line, Human Embryonic Kidney 293 (HEK293), did not form polymers on the cell surface ([Figure 3A](#fig3){ref-type="fig"}). Accordingly, only the longer polymerisation-incompetent uromodulin isoform was released by these cells ([Figure 3B](#fig3){ref-type="fig"}). We hypothesised that this was due to lack of expression of the proper serine protease responsible for physiological uromodulin cleavage. Under this assumption, we compared the expression profiles available in Gene Expression Omnibus of known serine proteases (about 220 enzymes) between MDCK and HEK293 cells, to identify those exclusively expressed by the former. Among the resulting 23 candidates we then selected only membrane-bound enzymes that were found to be expressed in available TAL segment transcriptomes ([@bib60]; [@bib9]). This strategy led to the identification of only four candidate enzymes: prostasin (Prss8), hepsin/TMPRSS1 (Hpn), mucin 1 (Muc1) and dipeptidyl-peptidase IV (Dpp4) ([Figure 3C](#fig3){ref-type="fig"}). The last two enzymes were excluded on the basis of their catalytic activity: Dpp4 sequentially removes N-terminal dipeptides from polypeptides, cleaving after a proline residue ([@bib36]), whereas Muc1 contains a self-cleaving module rather than a classical peptidase S1 domain ([@bib32]). Validation of transcriptome data confirmed differential expression of the two candidate proteases, hepsin and prostasin, in MDCK and HEK293 cells ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Interestingly, both proteases are inhibited by the Kunitz-type serine protease inhibitor HAI-1 ([@bib13]; [@bib22]), in line with our results in MDCK cells ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).10.7554/eLife.08887.009Figure 3.Hepsin and prostasin interact with uromodulin to induce its cleavage and polymerisation.(**A**) Immunofluorescence analysis (extended focus image) showing uromodulin on the surface of HEK293 cells. The protein is not assembled into polymers when expressed in this cellular system. Scale bar, 21 µm. (**B**) Representative Western blot analysis of N-deglycosylated uromodulin secreted by MDCK and HEK293 cells. HEK293 cells only secrete the longer polymerisation-incompetent uromodulin isoform (black arrowhead), while MDCK cells also secrete the shorter one (white arrowhead). (**C**) Schematic representation of the selection process employed to identify candidate enzymes for the secretion of the short uromodulin isoform. Only membrane-bound serine proteases specifically expressed by MDCK cells and by the TAL segment of the nephron, but not by HEK293 cells, were selected. (**D**) Representative Western blot analysis of N-deglycosylated uromodulin secreted by HEK293 cells expressing wild-type or catalytically inactive human hepsin or prostasin, as indicated. Only wild-type proteases promote the secretion of the short uromodulin isoform by these cells (white arrowhead). (**E**) Immunofluorescence analysis (extended focus image) showing uromodulin on the surface of HEK293 cells expressing wild-type or catalytically inactive hepsin or prostasin, as indicated. Uromodulin polymerisation is induced only when wild-type proteases are expressed. Scale bar, 21 µm. (**F**) Representative Western blot analysis of uromodulin immunoprecipitation (upper panels) from lysates of HEK293 cells expressing hepsin or prostasin, as indicated. Both enzymes are co-immunoprecipitated when uromodulin is co-expressed in HEK293 cells (lower panels). The arrowheads point at hepsin and prostasin specific bands.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.009](10.7554/eLife.08887.009)10.7554/eLife.08887.010Figure 3---figure supplement 1.Hepsin and prostasin expression in MDCK and HEK293 cells.(**A**) RT-PCR analysis showing gene expression of candidate proteases hepsin (*HPN*) and prostasin (*PRSS8*) in MDCK and HEK293 cells. Constructs containing coding sequences of the human proteases were used as PCR positive controls (C+). Expression of *GAPDH* is shown as a cDNA positive control. *PRSS8* and *HPN* are exclusively expressed in MDCK cells, confirming data obtained from available transcriptomes. (**B**) Representative Western blot analysis of uromodulin, hepsin and prostasin in lysates of transfected HEK293 cells. Wild-type proteases as well as catalytically inactive enzymes were expressed in HEK293 cells, as indicated. Protein disulfide-isomerase (Pdi) is shown as a loading control. The arrowhead points at hepsin specific band.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.010](10.7554/eLife.08887.010)

We validated our hypothesis by expressing either hepsin or prostasin in HEK293 cells. This induced short cleavage as well as polymerisation of uromodulin, an effect that was dependent on the catalytic activity of the enzymes, as it was abolished when catalytically inactive isoforms of the proteases were expressed ([Figure 3D,E](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Moreover, this effect is likely direct, as both enzymes could be specifically co-immunoprecipitated with uromodulin from the lysates of HEK293 cells ([Figure 3F](#fig3){ref-type="fig"}). Based on this observation, we assessed whether uromodulin can be directly cleaved by hepsin and prostasin *in vitro*. To do so, we carried out cleavage assays by employing a truncated recombinant form of uromodulin that corresponds to the elastase-resistant fragment of uromodulin from human urine (efUmod, lacking residues 27--294) ([@bib25]). We focussed on this fragment as it primarily consists of the ZP polymerisation domain ([Figure 4A](#fig4){ref-type="fig"}). Also, deletion of the N-terminal part of uromodulin greatly improved its purification efficiency (data not shown), probably because it lacks several N-glycosylation sites. Importantly, this isoform undergoes proper proteolytic cleavage and forms polymers in MDCK cells ([Figure 4B](#fig4){ref-type="fig"}). When incubated with purified efUmod, both hepsin and prostasin induced a mass shift of efUmod as well as loss of its C-terminal histidine tag ([Figure 4C](#fig4){ref-type="fig"}). These effects were abolished by mutagenesis of the consensus cleavage site (efUmod YAla, carrying the mutation ^586^RFRS^589^ \> ^586^AYAA^589^). Taken together, these findings indicate that hepsin and prostasin physically interact with uromodulin and cleave it at the physiological site. Interestingly, hepsin was more efficient than prostasin, since it completely digested the substrate despite being used at lower concentration (see figure legend).10.7554/eLife.08887.011Figure 4.Hepsin and prostasin directly cleave uromodulin *in vitro*.(**A**) Schematic representation of human uromodulin domain structure as shown in [Figure 1A](#fig1){ref-type="fig"}. The region not included in recombinant efUmod is shadowed. (**B**) The deletion of the elastase-sensitive fragment of uromodulin does not affect protein polymerisation on the surface of MDCK cells, as shown by immunofluorescence analysis (efUmod wt). As for full-length uromodulin ([@bib49]), this process depends on correct protein cleavage at the physiological site, since it is abolished when the consensus cleavage site is mutated (efUmod 4Ala, carrying the mutation ^586^RFRS^589^ \> ^586^AAAA^589^). Scale bar, 50 µm. (**C**) Purified efUmod, either wild-type (efUmod wt) or mutated at the consensus cleavage site (efUmod YAla, carrying the mutation ^586^RFRS^589^ \> ^586^AYAA^589^), was incubated with recombinant prostasin or hepsin, as indicated. Both proteases decrease the mass of wild-type efUmod (white arrowheads in upper and middle panels) and cause the loss of its C-terminal His-tag (lower panel). Hepsin is more efficient than prostasin, as it drives complete digestion of the product, despite being used at 20x lower concentration (picomolar ratio between protease and efUmod was 1:100 for hepsin and 1:5 for prostasin, see lanes 7 and 8 for comparison). The asterisk indicates His-tagged prostasin.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.011](10.7554/eLife.08887.011)

The two candidate proteases could not be discriminated on the basis of their subcellular localisation in MDCK cells. Indeed, while endogenous proteases could not be detected, possibly because of low expression levels or low affinity for the employed antibodies (which were raised against their human counterparts), transfected hepsin and prostasin both co-localised with uromodulin on the apical membrane of polarised MDCK cells ([Figure 5A](#fig5){ref-type="fig"}). Hence, we designed short hairpin RNAs (shRNAs) to specifically silence either protease in this cellular system. We successfully obtained comparable expression knock-down for both enzymes ([Figure 5B](#fig5){ref-type="fig"}), but only hepsin silencing led to a significant reduction of uromodulin polymerisation on the cell surface ([Figure 5C](#fig5){ref-type="fig"}). These results demonstrate that hepsin is the enzyme responsible for uromodulin cleavage at the urinary site in MDCK cells.10.7554/eLife.08887.012Figure 5.Hepsin is the protease mediating uromodulin polymerisation in MDCK cells.(**A**) Confocal immunofluorescence analysis showing uromodulin (green), hepsin or prostasin (red) and E-cadherin (blue) (basolateral membrane marker) in polarised MDCK cells, as indicated. Upper panels represent the reconstruction on the *xz* axis of merged *xy* scans, for which a representative image is shown in lower panels. Both serine proteases co-localise with uromodulin on the apical plasma membrane of polarised MDCK cells. *z* stacks = 0.3 µm. A: apical, BL: basolateral. Scale bars, 5 µm. (**B**) Transcript levels of *HPN* and *PRSS8*, as assessed by Real-Time qPCR in MDCK cells transfected with shRNA vectors, as indicated. Expression values (normalised to glyceraldehyde-3-phosphate dehydrogenase, GAPDH) are shown as relative to cells transfected with control vector. Expression of the proteases is specifically reduced in silenced cells. Bars indicate average ± s.e.m. \*\*p\<0.01, \*\*\*p\<0.001 (Student's *t* test). The graph represents mean ratios of 3 independent experiments ([Figure 5---source data 1](#SD3-data){ref-type="supplementary-material"}). (**C**) Immunofluorescence analysis showing uromodulin on the surface of MDCK cells transfected with control vector or with shRNA vectors targeting hepsin or prostasin, as indicated. Scale bar, 50 µm. Quantification of the average surface of uromodulin polymers shows that silencing of hepsin, but not of prostastin, substantially reduces uromodulin polymerisation on the membrane of MDCK cells. Bars indicate average ± s.e.m. \*\*\*p\<0.001 (Mann-Whitney test). The graph represents mean ratios of 3 independent experiments ([Figure 5---source data 2](#SD4-data){ref-type="supplementary-material"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.012](10.7554/eLife.08887.012)10.7554/eLife.08887.013Figure 5---source data 1.Transcript level of *HPN* and *PRSS8* in MDCK cells after shRNA transfection ([Figure 5B](#fig5){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.013](10.7554/eLife.08887.013)10.7554/eLife.08887.014Figure 5---source data 2.Quantification of the area of uromodulin polymers on the surface of MDCK cells after shRNA transfection ([Figure 5C](#fig5){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.014](10.7554/eLife.08887.014)

Hepsin mediates physiological cleavage and polymerisation of uromodulin *in vivo* {#s2-3}
---------------------------------------------------------------------------------

To understand the physiological relevance of our findings, we then investigated the expression of endogenous hepsin in mouse kidneys. Remarkably, by microdissecting mouse nephron segments, we detected strong hepsin expression in the TAL ([Figure 6A](#fig6){ref-type="fig"}). Moreover, hepsin co-localises with uromodulin on the apical membrane of TAL epithelial cells, suggesting a functional interaction between the two proteins ([Figure 6B](#fig6){ref-type="fig"}). To assess the role of hepsin in uromodulin processing *in vivo*, we characterised uromodulin urinary secretion in a previously generated *Hpn*^-/-^ mouse model, which does not show any gross phenotype or structural abnormality in major organs ([@bib59]). Notably, urinary uromodulin levels were significantly reduced in *Hpn*^-/-^ mice ([Figure 6C](#fig6){ref-type="fig"}). This was accompanied by marked accumulation of the mature, fully glycosylated form of uromodulin in kidney lysates ([Figure 6D](#fig6){ref-type="fig"}). On the other hand, no difference was observed in the cellular distribution of uromodulin in TAL cells, showing typical apical membrane enrichment ([Figure 6E](#fig6){ref-type="fig"}), and no change in *Umod* gene expression was detected ([Figure 6F](#fig6){ref-type="fig"}). These data exclude that reduced levels of urinary uromodulin in *Hpn*^-/-^ mice could be due to changes in protein expression or transport to the apical plasma membrane, strongly suggesting defective protein secretion.10.7554/eLife.08887.015Figure 6.Defective uromodulin urinary secretion in mice lacking hepsin.(**A**) Transcript level of *Hpn*, as assessed by Real-Time qPCR on microdissected nephron segments (normalised to *Gapdh*). Expression of *Hpn* is detected in proximal straight tubules (PST), thick ascending limb (TAL), proximal convoluted tubules (PCT), distal convoluted tubules (DCT) and, to a lesser extent, in collecting ducts (CD). Minimal expression of the protease is detected in glomeruli (GI). Bars indicate average ± s.e.m. of 3 independent experiments ([Figure 6---source data 1](#SD5-data){ref-type="supplementary-material"}). (**B**) Immunofluorescence analysis of mouse kidney sections showing co-localisation of endogenous hepsin and uromodulin on the apical plasma membrane of TAL epithelial cells. Scale bar, 20 µm. (**C**) Representative Western blot analysis of urinary uromodulin secretion in *Hpn*^-/-^ mice or control animals. Urinary protein loading was normalised to urinary creatinine concentration. Densitometric analysis shows reduced uromodulin urinary secretion in animals lacking hepsin (average ± s.d., n = 10/group, [Figure 6---source data 2](#SD6-data){ref-type="supplementary-material"}). \*\*\*p\<0.001 (Student's *t* test). (**D**) Western blot analysis of uromodulin in kidney lysates of *Hpn*^-/-^ mice or control animals. Beta-actin is shown as a loading control. Densitometric analysis shows accumulation of uromodulin in kidney lysates from *Hpn*^-/-^ mice (average ± s.d., n = 3/group, [Figure 6---source data 3](#SD7-data){ref-type="supplementary-material"}). \*\*p\<0.01 (Student's *t* test). (**E**) Representative immunofluorescence analysis showing apical plasma membrane signal of uromodulin in kidney sections from *Hpn*^-/-^ mice or control animals. Scale bar, 50 µm. (**F**) Transcript level of *Umod*, as assessed by Real-Time qPCR on total kidney extracts from *Hpn*^-/-^ mice or control animals (normalised to *Hprt1*). Expression of *Umod* is comparable between the two groups of animals (n = 3/group, [Figure 6---source data 4](#SD8-data){ref-type="supplementary-material"}). Bars indicate average ± s.e.m. (Student's *t* test).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.015](10.7554/eLife.08887.015)10.7554/eLife.08887.016Figure 6---source data 1.Transcript level of *Hpn* in mouse microdissected nephron segments ([Figure 6A](#fig6){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.016](10.7554/eLife.08887.016)10.7554/eLife.08887.017Figure 6---source data 2.Quantification of urinary uromodulin secretion in *Hpn*^-/-^ and control mice ([Figure 6C](#fig6){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.017](10.7554/eLife.08887.017)10.7554/eLife.08887.018Figure 6---source data 3.Quantification of uromodulin levels in kidney lysates of *Hpn*^-/-^ and control mice ([Figure 6D](#fig6){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.018](10.7554/eLife.08887.018)10.7554/eLife.08887.019Figure 6---source data 4.Transcript levels of *Umod* in *Hpn*^-/-^ and control mice ([Figure 6F](#fig6){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.019](10.7554/eLife.08887.019)

After deglycosylation, urinary uromodulin from *Hpn*^-/-^ mice appeared as two isoforms: a short one, with similar electrophoretic mobility as in wild-type urines, and a longer one, normally undetectable in urines from wild-type mice ([Figure 7A](#fig7){ref-type="fig"}). Mass-spectrometry analysis on the short isoform showed that it lacks the physiological C-terminus (F588) and is produced by a more distal cleavage occurring after residue R607 ([Figure 7B--D](#fig7){ref-type="fig"}). The same analysis on the long isoform revealed an even more distal C-terminus, after residue K616 ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}), consistent with its slower electrophoretic mobility. These data demonstrate that absence of hepsin abolishes uromodulin cleavage at the physiological site and induces its misprocessing. Interestingly, uromodulin from *Hpn*^-/-^ urines was not sedimented in the pellet fraction of a biochemical polymerisation assay ([@bib25]) ([Figure 7E](#fig7){ref-type="fig"}), indicating that the residual urinary protein is not assembled into polymers. This is consistent with the observation that both urinary isoforms in *Hpn*^-/-^ mice are misprocessed and still retain the polymerisation-inhibiting EHP motif ([Figure 7D](#fig7){ref-type="fig"}) ([@bib26]; [@bib49]).10.7554/eLife.08887.020Figure 7.Absence of hepsin *in vivo* abolishes physiological cleavage and polymerisation of uromodulin.(**A**) Representative Western blot analysis of N-deglycosylated urinary uromodulin secreted by *Hpn*^-/-^ mice or control animals. *Hpn*^-/-^ mice show the presence of two uromodulin isoforms: a short one with similar electrophoretic mobility as in wild-type urines (white arrowhead), and a longer one that is absent in samples from wild-type mice (black arrowhead) (n = 6/group). (**B**) Mass spectrometry (MS) sequence coverage (52% over the entire protein) of trypsin-digested mouse uromodulin (short isoform) (UniProt accession Q91X17) purified from urine of *Hpn*^-/-^ mice. Matching peptides are shown in red, while the C-terminal peptide is shown in blue. This peptide ends at R607, a distal C-terminal residue with respect to the one reported for mouse urinary uromodulin (F588 \[[@bib48]\]). (**C**) Representative tandem mass-spectrometry (MS/MS) spectrum, confirming the identity of the identified C-terminal peptide (^599^VLNLGPITR^607^) of the short uromodulin isoform released by *Hpn*^-/-^ mice, and table of fragmented ions. (**D**) Schematic representation of mouse uromodulin domain structure as in [Figure 1A](#fig1){ref-type="fig"}. The blow-up shows that in the absence of hepsin, the cleavage generating the short uromodulin isoform is abolished and alternative ones at more C-terminal sites (distal to R607) take place. (**E**) Representative Western blot analysis of uromodulin in supernatant (SN) and pellet (P) fractions from a polymerisation assay performed on urinary samples from *Hpn*^-/-^ mice or control animals. Urinary uromodulin from control animals is precipitated in the pellet fraction, reflecting full engagement in polymeric structures, while the one from *Hpn*^-/-^ mice is only detected in the supernatant (n = 4/group).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.020](10.7554/eLife.08887.020)10.7554/eLife.08887.021Figure 7---source data 1.Transcript level of *Prss8* in mouse microdissected nephron segments ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.021](10.7554/eLife.08887.021)10.7554/eLife.08887.022Figure 7---source data 2.Quantification of urinary uromodulin secretion in *Prss8*^-/-^ and control mice ([Figure 7---figure supplement 2C](#fig7s2){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.022](10.7554/eLife.08887.022)10.7554/eLife.08887.023Figure 7---figure supplement 1.Urinary uromodulin misprocessing in *Hpn*^-/-^ mice.(**A**) Mass spectrometry (MS) sequence coverage (51% over the entire protein) of trypsin-digested mouse uromodulin (long isoform) (UniProt accession Q91X17) purified from urine of *Hpn*^-/-^ mice. Matching peptides are shown in red, while the C-terminal peptide is shown in blue. This peptide ends at K616, a distal C-terminal residue with respect to the one reported for mouse urinary uromodulin (F588 \[Santambrogio et al., 2008\]). (**B**) Representative tandem mass-spectrometry (MS/MS) spectrum, confirming the identity of the identified C-terminal peptide (^608^QGVQASVSK^616^) of the long uromodulin isoform released by *Hpn*^-/-^ mice, and table of fragmented ions.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.023](10.7554/eLife.08887.023)10.7554/eLife.08887.024Figure 7---figure supplement 2.Uromodulin secretion is not affected by lack of prostasin *in vivo*.(**A**) Transcript level of *Prss8*, as assessed by Real-Time qPCR on microdissected nephron segments (normalised to *Gapdh*). Expression of *Prss8* is detected in proximal convoluted tubules (PCT), proximal straight tubules (PST) and, to a lesser extent, in thick ascending limb (TAL) and collecting ducts (CD). Bars indicate average ± s.e.m. of 3 independent experiments ([Figure 7---source data 1](#SD9-data){ref-type="supplementary-material"}). (**B**) Immunofluorescence analysis of mouse kidney sections shows strong signal of endogenous prostasin on the apical plasma membrane of proximal tubules, and weak signal on the apical plasma membrane of TAL epithelial cells where it co-localises with uromodulin. Scale bar, 20 µm. (**C**) Representative Western blot analysis of urinary uromodulin from control *Prss8^lox/lox^*or *Prss8*^-/-^ mice. Urinary protein loading was normalised to urinary creatinine concentration. Densitometric analysis shows that uromodulin secretion is comparable between *Prss8*^-/-^ mice and control *Prss8^lox/lox^*animals (average ± s.d., n = 5/group, [Figure 7---source data 2](#SD10-data){ref-type="supplementary-material"}) (Student's *t* test). (**D**) Representative Western blot analysis of N-deglycosylated urinary uromodulin secreted by *Prss8*^-/-^ mice or control animals. An isoform of identical molecular weight, corresponding to the short uromodulin isoform, is detected in urine samples of both genotypes (n = 5/group). (**E**) Mass spectrometry sequence coverage (55% over the entire protein) of AspN-digested mouse uromodulin (UniProt accession Q91X17) purified from urine of *Prss8*^-/-^ mice. Matching peptides are shown in red, while the C-terminal peptide is shown in blue. This peptide ends at F588, the same C-terminal residue identified in urinary uromodulin of wild-type mice (Santambrogio et al., 2008) and control *Prss8^lox/lox^*animals (data not shown). (**F**) Representative MS/MS spectrum confirming the sequence of urinary uromodulin C-terminal peptide (^573^DSTSEQCKPTCSGTRF^588^) in *Prss8*^-/-^ mice and table of fragmented ions.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.024](10.7554/eLife.08887.024)

A role for hepsin in the activation of prostasin, whose zymogen is unable to auto-activate, was demonstrated *in vitro* ([@bib8]). To assess whether the results observed in *Hpn*^-/-^ mice could be due to the lack of hepsin-mediated activation of prostasin, we first investigated the expression pattern of endogenous prostasin in mouse kidneys. Confirming data from available transcriptomes, we detected weak prostasin expression in TAL segments where it co-localises with uromodulin on the apical plasma membrane of epithelial cells ([Figure 7---figure supplement 2A,B](#fig7s2){ref-type="fig"}). We then generated an adult nephron-specific *Prss8^-/-^* mouse model and analysed urinary uromodulin. Secretion of urinary uromodulin in these mice was comparable to controls ([Figure 7---figure supplement 2C,D](#fig7s2){ref-type="fig"}). Moreover, mass-spectrometry analysis on the urinary protein confirmed that it shares the same C-terminal residue of control animals ([Figure 7---figure supplement 2E,F](#fig7s2){ref-type="fig"}), excluding a role for prostasin in uromodulin processing *in vivo*.

Discussion {#s3}
==========

Collectively, our results identify hepsin as the enzyme responsible for the physiological release of uromodulin in the urine. Hepsin, or TMPRSS1, is a member of type II transmembrane serine proteases. It is expressed in several tissues and it has been previously implicated in the processing of different substrates; however, the physiological relevance of most of these observations remains to be established ([@bib8]; [@bib23]; [@bib28]; [@bib15]). By identifying hepsin as the enzyme responsible for the release of uromodulin in the renal tubule, our results reveal an important biological function of this type II transmembrane serine protease in the renal epithelium. At the same time, they represent a major advancement in understanding the biology of uromodulin, opening new avenues of research on the regulation and possibly modulation of its secretion. This could have impact for diseases such as urolithiasis where the urinary levels of uromodulin may be directly correlated with its protective function. Also, it might be relevant for CKD and hypertension where we demonstrated that *UMOD* risk variants are associated with increased uromodulin expression and urinary levels ([@bib58]; [@bib39]). Lack of hepsin does not affect baseline renal function of *Hpn*^-/-^ mice (serum creatinine: wild-type 0.78 +/- 0.04 vs *Hpn*^-/-^ 0.74 +/- 0.14 mg/dL, n = 5/group, p=0.59; blood urea nitrogen: wild-type 21.6 +/- 3.29 vs *Hpn*^-/-^ 20.8 +/- 4.12 mg/dL, n= 5/group, p=0.76). In this light, further studies in *Hpn*^-/-^ mice with altered uromodulin processing and secretion are warranted to investigate if the mice develop a phenotype upon additional challenges. The results may provide new insight into uromodulin cellular and extracellular functions.

It is well recognised that proteolysis plays a central role in uromodulin polymerisation. This step leads to the release of an inhibitory intramolecular interaction that prevents premature protein polymerisation ([@bib26]; [@bib49]; [@bib19]). Considering the maturation steps of uromodulin along the secretory compartment, hepsin-mediated cleavage likely takes place at the plasma membrane where the two proteins co-localise, allowing the protein to traffic within the cell in a polymerisation-incompetent conformation, and to polymerise only once it is secreted ([Figure 8](#fig8){ref-type="fig"}). Interestingly, the C-terminus of human and mouse urinary uromodulin has been mapped to a phenylalanine residue (F587 and F588, respectively) ([@bib48]). Since *in vitro* studies showed that hepsin preferentially cleaves substrates after basic amino acids ([@bib22]; [@bib5]; [@bib40]), this could result from cleavage at the following arginine residue and subsequent C-terminal trimming. Post-cleavage trimming by carboxypeptidases is not uncommon and it has already been proposed for several secreted proteins, including urokinase ([@bib18]), and ZP subunits ([@bib29]; [@bib4]; [@bib10]).10.7554/eLife.08887.025Figure 8.Model of uromodulin shedding and polymerisation.Uromodulin is exclusively expressed by TAL tubular epithelial cells. The protein enters the secretory pathway and reaches the plasma membrane in a polymerisation-incompetent conformation. This is ensured by the interaction between two hydrophobic patches within and next to the ZP-C subdomain (Internal Hydrophobic Patch, red circle, and External Hydrophobic Patch, dark green circle) ([@bib26]; [@bib49]; [@bib19]). Shedding by hepsin at the uromodulin consensus cleavage site (red diamond), likely occurring at the plasma membrane, releases the hydrophobic interaction, generating polymerisation-competent species that are assembled into polymeric filaments within the tubular lumen. Pink circles indicate N-terminal EGF-like domains, yellow and green cylinders represent ZP-N and ZP-C subdomains. The orientation of uromodulin within polymers is hypothetical.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.025](10.7554/eLife.08887.025)

Through the identification of hepsin as the protease releasing uromodulin in the urine we discover the first protease involved in the physiological cleavage of a ZP domain protein, which is a pre-requisite for polymerisation of this type of molecules. Notably, *Hpn*^-/-^ mice were reported to have profound hearing loss likely due to inner ear defects, including a deformed and enlarged tectorial membrane ([@bib17]). This acellular structure, which overlays the organ of Corti, consists of filaments largely composed of ZP domain proteins α- and β-tectorin. The morphology of the tectorial membrane is similarly altered in mice carrying deafness-causing mutations in α-tectorin ([@bib31]) that are likely affecting protein secretion ([@bib25]). These findings, along with data presented in this manuscript, suggest that inner ear tectorins are also physiological substrates of hepsin. Moreover, release of glycoprotein-2, a ZP domain protein highly homologous to uromodulin that is predominantly expressed in pancreas, is mediated by an apical protease sensitive to serine protease inhibitors ([@bib14]), again suggesting the involvement of hepsin. In light of these observations and given the conserved function of the ZP domain and the high similarity of the consensus cleavage site of ZP domain proteins ([@bib26]), our results are likely to be relevant for other members of this protein family.

Materials and methods {#s4}
=====================

Constructs {#s4-1}
----------

Uromodulin vectors expressing wild-type HA- or FLAG-tagged protein, soluble mutant S614X and consensus cleavage site mutant ^586^RFRS^589/586^AAAA^589^ (4Ala mutant) have already been described ([@bib49]; [@bib50]). A gene encoding the elastase-resistant fragment of uromodulin (efUmod, lacking residues 27--294) was generated by overlapping PCRs (PCR1: residues 1--26; PCR2: residues 295--640) from wild-type uromodulin cDNA and inserted in pcDNA 3.1(+) (Life Technologies, Carlsbad, CA) for expression studies in MDCK cells. To generate soluble efUmod for *in vitro* cleavage experiments, a DNA fragment encoding uromodulin residues 295--610 was cloned in pIRES-hrGFP II (Stratagene, Santa Clara, CA). Glycosylation site mutation N513Q and a C-terminal 6His-tag were inserted. The consensus cleavage site mutant ^586^RFRS^589^ \> ^586^AYAA^589^ was also generated by site-directed mutagenesis (QuikChange Lightning Site-Directed mutagenesis kit, Agilent Technologies, Santa Clara, CA). Human hepsin and prostasin cDNA (OriGene, Rockville, MD) were cloned in pcDNA3.1/Zeo(+) (Life Technologies). Myc-tag was inserted at the C-terminus of hepsin by phosphorylating and annealing the following primers: forward 5'-CCGGTGAGCAAAAGCTGATTTCTGAGGAGGATCTGA-3' and reverse 5'- CCGGTCAGATCCTCCTCAGAAATCAGCTTTTGCTCA -3'. Catalytically inactive prostasin or hepsin were generated by mutating the serine residue of the catalytic triad (S238A in PRSS8, S353A in HPN) using the QuikChange Lightning Site-Directed mutagenesis kit (Agilent Technologies). Primer sequences for generation of all constructs are listed in [Table 1](#tbl1){ref-type="table"}.10.7554/eLife.08887.026Table 1.Primers (5\'-3\') used to generate *UMOD* and protease constructs.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.026](10.7554/eLife.08887.026)efUMOD-PCR1\
T7: TAATACGACTCACTATAGGG\
Reverse: ACACGTCCCCTCCACGTGGTGATGGTGATGATGACefUMOD-PCR2\
Forward: CATCACCATCACCACGTGGAGGGGACGTGTGAGGA\
BGHrev: TAGAAGGCACAGTCGAGGefUMOD_sol\
Forward: GGACAGATCTACGTCGACGGGACGTGTGAGGAGTGCAG\
Reverse: CCGGAATTCCTAGTGATGATGGTGATGATGCTGGACACCTTTCCGTGTGefUMOD_AYAA\
Forward: CCTACCTGCTCTGGGACCGCATACGCAGCTGGGAGTGTCATAGATCAATCCC\
Reverse: GGGATTGATCTATGACACTCCCAGCTGCGTATGCGGTCCCAGAGCAGGTAGGefUMOD_N513Q\
Forward: CACCCAGTAGCCAGGCCACGGACCCCC\
Reverse: GGGGGTCCGTGGCCTGGCTACTGGGTGPRSS8_S238A\
Forward: GCCAGGGTGACGCTGGGGGCCCA\
Reverse: TGGGCCCCCAGCGTCACCCTGGCHPN_S353A\
Forward: CTGCCAGGGCGACGCCGGTGGTCCCTTT\
Reverse: AAAGGGACCACCGGCGTCGCCCTGGCAG

Human HAI-1 cDNA ([@bib55]) cloned in pcDNA3.1(+) was a kind gift of Prof. Clara Camaschella (San Raffaele Scientific Institute).

Cell lines and culture conditions {#s4-2}
---------------------------------

Madin-Darby Canine Kidney (MDCK) cells and Human Embryonic Kidney 293 (HEK293) cells were grown in DMEM supplemented with 10% foetal bovine serum (Euroclone, Pero, Italy), 200 U/ml penicillin, 200 μg/ml streptomycin, and 2 mM glutamine at 37°C with 5% CO~2~. They were transfected using Lipofectamine 2000 (Life Technologies) or Metafectene Pro (Biontex, Munich, Germany) respectively. Selection of stably transfected MDCK cells with G418 (Life Technologies) was started 24 hr after transfection and was pursued for 1--2 weeks. To obtain electrically tight monolayers (\>100 Ω cm^-2^), MDCK cells were grown on filters (Corning, Corning, NY) for 4 days. Uromodulin secretion in MDCK or HEK293 cells was analysed after 16 hr incubation in Optimem (Life Technologies).

Cellular treatment with protease inhibitors {#s4-3}
-------------------------------------------

MDCK cells stably expressing uromodulin were grown on coverslip. After 24 h, the medium was replaced with Optimem supplemented with 0.1% protease inhibitor cocktail (PIC) (P8340, Sigma-Aldrich, Saint Louis, MO), 0.1% DMSO, 0.1 mM AEBSF, 0.08 μM aprotinin, 1.4 μM E64, 4 μM bestatin, 2 μM leupeptin and 1.5 μM pepstatin A (Sigma-Aldrich). Immunofluorescence analysis was performed after 24 hr of treatment.

Silencing of hepsin and prostasin expression {#s4-4}
--------------------------------------------

Sfold (<http://sfold.wadsworth.org/cgi-bin/index.pl>) and siDESIGN center (<http://www.thermoscientificbio.com/design-center/>) were used to identify siRNAs targeting canine hepsin and prostasin. Selected oligos (sense sequence) are listed in [Table 2](#tbl2){ref-type="table"}. Oligonucleotides for shRNA strategy were designed combining the siRNA sequence (sense) followed by a loop (sequence 5'-3': TTCAAGAGA), the reverse complement of the siRNA sequence (antisense) and RNA polymerase III terminator (sequence 5'-3': TTTTTTGGAA). Oligos were phosphorylated, annealed and inserted in pENTR/pTER+, a gift from Eric Campeau (plasmid \# 17453, Addgene, Cambridge, MA) ([@bib6]). MDCK cells stably expressing uromodulin were co-transfected with pENTR/pTER+ vector and EGFP-expressing vector pcDNA3x(+)MyEGFP (Life Technologies). Cells were collected 24 hr after transfection and sorted using MoFlo sorter (Beckman Coulter, Brea, CA). Recovered EGFP-positive cells were maintained in culture for 48 hr.10.7554/eLife.08887.027Table 2.Oligonucleotide sequences used to generate shRNAs.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.027](10.7554/eLife.08887.027)Target geneTarget position from ATG codonsiRNA oligo (5'-3')*HPN\_*siRNA\#1122-140CCTTCCTACTCAAGAGTGA*HPN\_*siRNA\#21195-1213TGGATCTTCCAGGCCATAA*PRSS8\_*siRNA\#1258-276GAAGGAAGACTATGAGGTA*PRSS8\_*siRNA\#2593-611TGTACAACATCAACGCTAAControl siRNANATAGTGAGATTCGTTAAGAT

*In silico* analyses {#s4-5}
--------------------

A list of human serine proteases was derived from the MEROPS database (<http://merops.sanger.ac.uk/>). The expression profile of these enzymes in MDCK and HEK293 cells was analysed in Gene Expression Omnibus DataSets database (<http://www.ncbi.nlm.nih.gov/gds>) using baseline replicates of the following series: GSD3267 ([@bib21]), GSE20193 ([@bib53]), GSE18739 ([@bib2]), GSE15575 ([@bib1]), GSE1309 ([@bib61]), GSE1364 ([@bib24]), GSE51118 and GDS1852 ([@bib12]). Membrane association of the enzymes was derived from Uniprot database (<http://www.uniprot.org/>). Protease expression in TAL cells was analysed by including series GSE13672 ([@bib60]) and GSE25223 ([@bib9]).

Mouse lines {#s4-6}
-----------

Wild-type, *Hpn*^-/-^ ([@bib59]), *Prss8^lox/lox^*([@bib47]) and *Prss8^-/-^* animals are in C57BL/6J background. Adult nephron-specific *Prss8*-deficient (*Prss8^-/-^*) mice were obtained by interbreeding of *Prss8^lox/lox^* with *Pax8-rtTA/LC1^tg/+^* ([@bib57]). Briefly, 28 day-old *Prss8^-/-^* and *Prss8^lox/lox^* (control) littermates were treated with doxycycline (2 mg/ml) in 2% sucrose in drinking water for 15 days. Genotyping by PCR was performed as previously described ([@bib35]; [@bib46]).

All animal procedures were carried out at the Lerner Research Institute, Cleveland Clinic, USA; at the University of Lausanne, Lausanne, Switzerland and at the University of Zurich, Zurich, Switzerland, according to protocols approved by the Institutional Animal Care and Use Committee at the Lerner Research Institute and by the Swiss Cantonal Veterinary Authority.

Protein extracts, immunoprecipitation and Western blot analysis {#s4-7}
---------------------------------------------------------------

MDCK and HEK293 cells, or mouse tissues were solubilised in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 60 mM octyl-β-D-glucopyranoside and 0.1% PIC). Cell-conditioned medium or urinary proteins were precipitated with acetone and resuspended in PBS. When needed, samples were N-deglycosylated with PNGase F (New England Biolabs, Ipswich, MA). Lysates were quantified with the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA).

Precleared lysates of HEK293 cells (300 µg) were loaded onto protein G Sepharose beads (Sigma-Aldrich) pre-conjugated with 2 µg of mouse anti-HA antibody (Covance, Princeton, NJ) and incubated 16 hr at 4°C. After washes in PBS-triton 0.5%, beads were resuspended in Laemmli Buffer.

Protein lysates, immunoprecipitated proteins, urinary or secreted proteins were separated on reducing 8% SDS-PAGE gel and transferred onto nitrocellulose membrane (GE Healthcare, Little Chalfont, United Kingdom). Western blotting (WB) was performed following standard protocols. Quantification was performed using the gel analysis option of ImageJ software (<http://rsbweb.nih.gov/ij/>) ([@bib51]).

Collection and processing of plasma, urine samples and renal tissues {#s4-8}
--------------------------------------------------------------------

Kidneys for immunofluorescence or microdissection of nephron segments were collected from 2--3-month-old male wild-type control mice. Nephron segment microdissection was performed and validated as previously described ([@bib16]). Plasma, urine and kidneys from wild-type and *Hpn*^-/-^ mice were collected from 2.5-month-old male mice. Urine and kidneys from *Prss8^lox/lox^*and *Prss8^-/-^* were collected from 1.5-month-old mice.

Animals were housed in a light- and temperature-controlled room with *ad libitum* access to tap water and standard chow. Urine collections (16 h) were obtained at baseline using individual metabolic cages, after appropriate training. Urinary creatinine quantification was performed using creatinine assay kit (Cayman Chemical, Ann Arbor, MI). Blood samples were collected from the vena cava. Serum creatinine levels were measured by Consolidated Veterinary Diagnostics (West Sacramento, CA). Polymerisation assay on urinary samples was performed as previously described ([@bib25]). Supernatants were precipitated with acetone, while pellets were solubilised in Laemmli Buffer.

Immunofluorescence analysis {#s4-9}
---------------------------

Immunofluorescence (IF) of cells grown on coverslip was carried out as previously described ([@bib49]). Cells grown on filters were fixed 20 min in 4% paraformaldehyde (VWR International, Radnor, PA) and permeabilised 15 min at 37°C with 0.7% gelatin and 0.016% saponin. Cells were incubated for 1 hr at 37°C with primary antibody and subsequently with the appropriate AlexaFluor-labeled secondary antibody (Life Technologies). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, Life Technologies) and slides were mounted using fluorescent mounting medium (Dako, Agilent Technologies). Slides were visualised under a DM 5000B fluorescence upright microscope (Leica, Wetzlar, Germany) or under an UltraVIEW ERS spinning disk confocal microscope (PerkinElmer, Waltham, MA). Quantification of mean polymeric area was performed using ImageJ software, as previously described ([@bib50]). Polymers were quantified on 5--9 independent images for each condition taken at 10x magnification. Cell and polymer reconstructions were carried out by collecting stacks of consecutive confocal images at 0.5 μm intervals. Extended focus 2D images were obtained by using Volocity 3D Image Analysis Software version 6.3 (PerkinElmer, Waltham, MA).

Kidneys for immunofluorescence were collected from mice anaesthetised and perfused with 3% paraformaldehyde and snap-frozen in liquid propane. Kidney sections (4--5 μm thick) were reactivated in PBS for 30 min and blocked with 10% goat serum for 30 min. They were incubated overnight at 4°C with with relevant primary antibodies (anti-hepsin, -prostasin or --uromodulin). For co-localisation with uromodulin, sections were blocked again for 30 min and incubated for 2 hr with the anti-uromodulin primary antibody. Slides were incubated with the appropriate AlexaFluor-labelled secondary antibody diluted in PBS containing DAPI and mounted with Prolong Gold anti-fade reagent (Invitrogen, Life Technologies). Slides were visualised with a Leica SP5 Confocal microscope.

Antibodies {#s4-10}
----------

We used the following primary antibodies: mouse anti-HA (MMS-101P, 1:1000 for WB and 1:500 for IF, Covance), rabbit anti-FLAG (F7425, 1:500 for IF, Sigma-Aldrich), goat anti-Myc (NB600-335, 1:500 for IF, Novus Biologicals, Littleton, CO), sheep anti-uromodulin (T0850, 1:1000 for WB, US Biological, Salem, MA), sheep anti-uromodulin (K90071C, 1:200 for IF, Meridian Life Science, Cincinnati, OH), goat anti-uromodulin (55140, 1:1000 for WB and 1:500 for IF, MP Biomedicals, Santa Ana, CA), rabbit anti-hepsin (100022, 1:1000 for WB and 1:50 for IF, Cayman Chemical), sheep anti-prostasin (AF4599, 1:1000 for WB and 1:200 for IF, R&D System, Minneapolis, MN), rabbit anti-prostasin (kind gift of Prof. Carl Chai, University of Central Florida College of Medicine, FL; 1:200 for IF) ([@bib7]), rabbit anti-HAI-1 (H-180, 1:1000 for WB, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-PDI (H-160, 1:1000 for WB, Santa Cruz Biotechnology), mouse anti-E-cadherin (610182, 1:500 for IF, BD Biosciences, San Jose, CA), mouse anti-KDEL (ADI-SPA-827-D, 1:500, Enzo Life Sciences, Farmingdale, NY), mouse anti-GAPDH (6C5, 1:5000 for WB, Santa Cruz Biotechnology), mouse anti-β actin (A2228, 1:16000 for WB, Sigma-Aldrich), mouse anti-α tubulin (SC-8035, 1:1000 for WB, Santa Cruz Biotechnology) and mouse anti-5His (34660, 1:1000 for WB, Qiagen, Venlo, The Netherlands).

RNA extraction, RT-PCR and Real-Time qPCR {#s4-11}
-----------------------------------------

Total RNA was extracted from confluent cells or from mouse kidneys using TRIzol reagent (Life Technologies) and reverse-transcribed using iScript kit (Bio-Rad). Expression of target genes was analysed by RT-PCR (\@Taq, Euroclone) or by Real-Time qPCR on LightCycler 480 (Roche, Basel, Switzerland) using qPCR Core kit for SYBR Assay (Eurogentec, Seraing, Belgium).

*Hpn* and *Prss8* expression in microdissected nephron segments were assessed by Real-Time qPCR with a CFX96^TM^ Real-Time PCR Detection System (Bio-Rad) using iQ^TM^ SYBR Green Supermix (Bio-Rad). The relative mRNA expression of genes of interest was calculated following the ΔΔCt method ([@bib42]). Primer sequences are listed in [Table 3](#tbl3){ref-type="table"} and [Table 4](#tbl4){ref-type="table"}.10.7554/eLife.08887.028Table 3.Primers used for gene expression analysis (RT-PCR).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.028](10.7554/eLife.08887.028)GenePCR product lengthPrimer (5'-3')*HPN*\
(Dog / Human)353 bpForward: GCTGCGAGGAGATGGGCTTC\
Reverse: CGGGAAGCAGTGGGCGGCTG*PRSS8*\
(Dog / Human)547 bpForward: CCTGGCAGGTCAGCATCACC\
Reverse: CCAGAGTCACCCTGGCAGGC*GAPDH*\
(Human)314 bpForward: CCACCCAGAAGACTGTGGAT\
Reverse: GTTGAAGTCAGAGGAGACCACC*GAPDH*\
(Dog)289 bpForward: CTCTGGGAAGATGTGGCGTGAC\
Reverse: GTTGAAGTCACAGGAGACCACC10.7554/eLife.08887.029Table 4.Primers used for gene expression analysis (Real-Time qPCR).**DOI:** [http://dx.doi.org/10.7554/eLife.08887.029](10.7554/eLife.08887.029)GenePCR product lengthPrimer (5'-3')*HPN*\
(Dog)164 bpForward: TGGTCCACCTGTCCAGCCCC\
Reverse: GACTCGGGCCTCCTGGAGCA*Hpn*\
(Mouse)152 bpForward: CTGACTGCTGCACATTGCTT\
Reverse: GGGTCTCGAAAGGGAAGGTA*PRSS8*\
(Dog)156 bpForward: TCCGGACTTGCCTTCTGCGGT\
Reverse: AGCTGAGAGCACCCACTGCTCA*GAPDH*\
(Dog)289 bpForward: CTCTGGGAAGATGTGGCGTGAC\
Reverse: GTTGAAGTCACAGGAGACCACC*Prss8*\
(Mouse)147bpForward: ATCACCCACTCAAGCTACCG\
Reverse: AGTACAGTGAAGGCCGTTGG*Umod*\
(Mouse)207 bpForward: ATGGACCAGTCCTGTCCTG\
Reverse: CCGTCTCGCTTCTGTTGAGT*Hprt1*\
(Mouse)162 bpForward: ACATTGTGGCCCTCTGTGTG\
Reverse: TTATGTCCCCCGTTGACTGA

Statistical analysis {#s4-12}
--------------------

Comparisons between groups were performed using two-tailed unpaired t-test or Mann-Whitney test. We expressed continuous measures as the mean ± the standard deviation (s.d.); averages of measurements as the mean ± the standard error of the mean (s.e.m.). We set significance level to p\<0.05.

Purification of efUmod and *in vitro* cleavage {#s4-13}
----------------------------------------------

Chinese Hamster Ovary (CHO) DG44 cells were grown in α-MEM medium supplemented with 10% foetal bovine serum (Life Technologies) and stably transfected with pIRES-hrGFP_efUMOD. Stable cells were cultured in HyQ SFM4CHO-utility medium (Thermo Scientific, Waltham, MA). efUmod secreted by CHO cells was purified by batch IMAC with Ni-NTA Superflow (Qiagen), followed by SEC using a HiLoad 26/60 Superdex 200/HiPrep 26/60 Sephacryl 200 double column system (GE Healthcare) equilibrated against 10 mM Tris-HCl pH 8.0 at 4°C, 50 mM NaCl, and concentration. Recombinant efUmod (25 ng/µl) was incubated with human serine proteases hepsin (Enzo Life Sciences, Farmingdale, NY) or prostasin (R&D System) in 50 mM Tris, 20 mM NaCl, pH 7.8 at 37°C for 10 hr. Picomolar ratio between protease and efUmod was 1:100 for hepsin and 1:5 for prostasin.

Electron microscopy of uromodulin filaments secreted by MDCK cells {#s4-14}
------------------------------------------------------------------

MDCK cell conditioned media were centrifuged 30 min at 18,000 x *g* at 4°C, resuspended in ultrapure water and applied to glow-discharged 400 mesh copper grids with a carbon support film. After 5 min the grids were washed with ultrapure water for 2 min and then negatively stained with 2% uranyl acetate. Samples were analysed using a CM120 electron microscope (Philips, Eindhoven, The Netherlands) equipped with a LaB~6~ electron source. Images were recorded on Kodak SO163 electron film (Eastman Kodak, Rochester, NY) and digitised using an Epson Perfection 4990 PHOTO flatbed scanner (Epson, Suwa, Japan).

Mass spectrometric analysis of uromodulin secreted by MDCK cells {#s4-15}
----------------------------------------------------------------

MDCK cell-conditioned media were centrifuged at 3,000 x *g* for 5 min at 4°C. Supernatants were concentrated using Amicon Ultra-3K (Millipore, Billerica, MA) at 4,000 x *g* at 4°C and depleted of the most abundant proteins using IgY-12 columns (Genway, San Diego, CA). Proteins were precipitated with 60% TCA (trichloroacetic acid, Sigma-Aldrich) for 1 hr at -20°C and washed with 90% acetone. Two hundred µg were diluted in 130 µl of a buffer containing 5 M urea (Sigma-Aldrich), 2 M thiourea (Sigma-Aldrich), 2% CHAPS (Sigma-Aldrich), 2% Zwittergent (GE Healthcare), 100 mM DeStreak (GE Healthcare) and 0.5% IPG buffer pH 3--10 NL (GE Healthcare) and loaded on Immobiline Dry strip pH 3--10 NL, 7 cm (GE Healthcare, total focusing run 50,000 Vh). IPG strips were sequentially reduced and alkylated prior to the second dimension electrophoresis. SDS-PAGE 8% gels were Coomassie stained and spots of interest were excised and in-gel digested as previously reported ([@bib54]). For nLC-MS/MS analysis, peptide mixtures were acidified up to 1% formic acid and analysed on an API QStar PULSAR (AB-Sciex, Framingham, MA) mass spectrometer as previously reported ([@bib34]). All MS/MS samples were analysed using MASCOT engine (version 2.2.07, Matrix Science, London, United Kingdom) and X!Tandem (within Scaffold software, v.3.6.4, Proteome Software, Portland, OR) to search the UniProt_CP_Human 2013_05 database. Peptide mass tolerance of 200 ppm and 0.6 Da for precursor and fragment ions were selected respectively. Searches were performed with: semi-Lys-C or semi-Asp-N specificity; carbamidomethylation of cysteine as fixed modification and oxidation of methionine as variable modification. Scaffold was used to validate MS/MS based peptide and protein identifications with protein thresholds set to 99%, 2 peptides minimum and peptide thresholds set to 95% minimum.

Mass spectrometric analysis of urinary uromodulin {#s4-16}
-------------------------------------------------

Uromodulin was purified from 1 ml of mouse urinary samples as previously described ([@bib48]). PNGase F-treated and alkylated samples were separated on 8% SDS--PAGE gel. Bands of interests were excised from Coomassie stained gels, reduced, alkylated and finally digested overnight with trypsin or Asp-N (Roche) ([@bib48]). After acidification, peptide mixtures were concentrated and desalted on homemade Stagetips µC18 ([@bib44]) and injected in a capillary chromatographic system (EasyLC, Proxeon Biosystems, Thermo Scientific). Peptide separations occurred on a homemade fused silica capillary column (75 μm i.d. × 25 cm), packed with 3 μm ReproSil-Pur C18-AQ (Dr. Maisch, Ammerbuch-Entringen, Germany). A gradient of eluents A (H~2~O with 2% acetonitrile, 0.5% acetic acid) and B (80% acetonitrile with 0.5% acetic acid) was used to achieve separation, from 4% to 70% B (in 65 min, 0.15 μL/min flow rate). The LC system was connected to an LTQ-Orbitrap mass spectrometer (Thermo Scientific) equipped with a nanoelectrospray ion source (Proxeon Biosystems). MS and MS/MS spectra were acquired selecting the ten most intense ions per survey spectrum acquired in the orbitrap from *m/z* 300--1750 with 60,000 resolution. Target ions selected for the MS/MS were fragmented in the ion trap and dynamically excluded for 120 sec. Target values were 1,000,000 for survey scan and 100,000 for MS/MS scan. MS/MS spectra were converted into peaklist (.msm files) and analysed using MASCOT and Scaffold searching against the UniProt_CP_Mus 2012_10 database. Searches were performed with: semi-Asp-N or semi-trypsin specificity; parent ion tolerance of 5.0 ppm and fragment ion mass tolerance of 0.60 Da; N-ethylmaleimide or carbamidomethyl of cysteine as fixed modifications; oxidation of methionine, asparagine deamidation and acetylation of the N-terminus of proteins as variable modifications.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"The serine protease hepsin mediates urinary secretion and polymerisation of Zona Pellucida domain protein uromodulin\" for peer review at *eLife*. Your submission has been favorably evaluated by Tony Hunter (Senior editor and Reviewing editor) and two reviewers.

The Reviewing editor has drafted this decision to help you prepare a revised submission.

We have received reviews from two experts, who found your observations to be a significant advance in our understanding of how uromodulin, in particular, and potentially other ZP proteins are processed. However, Reviewer \#2 and the BRE (Board of Reviewing Editors) member both felt that the paper would be significantly strengthened by the addition of evidence that this function of hepsin is physiologically important. For instance, if your major conclusion is correct, then one would expect to observe some renal effects in the hepsin knockout mice. For instance, do these mice exhibit increased urinary tract infection or other predictable renal phenotypes? If you can include data along these lines and address the other points raised by Reviewer 1, then we would consider a revised version of your paper for publication in *eLife*.

*Reviewer \#1:*

This is an interesting and exciting paper that provides very convincing evidence that hepsin (TMPRSS1) is the protease that regulates the proteolytic release of the ZP domain protein uromodulin from the apical plasma membrane of renal tubule cells, thereby allowing its polymerization. The work has been performed to a high standard, and the findings represent a significant advance that should be of wide interest considering the large number of ZP-domain proteins with diverse functions that have been identified. I have, however, a few questions and comments the authors could address.

1\) What is known about the longer and more abundant isoform of uromodulin that is secreted by transfected MDCK cells? How has it been secreted if it has not been released from the membrane? Is the sample shown in [Figure 1D](#fig1){ref-type="fig"} from the medium?

2\) PIC and some of the component proteases certainly reduce the numbers of cells that are expressing uromodulin polymers on their surface. Do the inhibitors affect overall protein expression levels in any way? Could it be that many of the cells are compromised in some fashion?

3\) [Figure 3D](#fig3){ref-type="fig"}: It is hard to see that uromodulin polymerization only occurs when wild type proteases are expressed. The images are not that convincing and could be improved. Some confocal images, and possibly some z-projections, may help here.

4\) In the first paragraph of the subsection "Hepsin mediates physiological cleavage and polymerisation of uromodulin in vivo": What is meant by the \'mature\' form of uromodulin? And what is the longer isoform shown in [Figure 7A](#fig7){ref-type="fig"} (right)? Is this partially N-deglycosylated? The text reads as if the short uromodulin isoform that is seen in the *Hpn^-/-^* mice is the same as that seen in the wild-type mice, when it is presumably not, as it lacks the physiological C-terminus. Some clarification is required here.

5\) Is prostasin expressed on the surface of the TAL in mouse kidney and does it co-localize with uromodulin?

6\) It is certainly intriguing that the phenotype of the tectorial membrane in the inner ear of *Hpn^-/-^* mice is morphologically very similar (at the light microscope level) to that seen in mice that are heterozygous for deafness-causing, semi-dominant missense mutations in the ZP domain of Tecta. Mutations in ZP2 corresponding to two of these Tecta ZP domain mutations (C1837G and Y1870C) have been shown to prevent the secretion of ZP2 in vitro (Jovine et al., 2002).

*Reviewer \#2:*

The biochemistry and discovery of the protease responsible for cleaving uromodulin are compelling. However, it is disappointing that there wasn\'t any evidence to suggest hepsin is physiologically important. Based on their data showing reduced secretion of uromodulin -- one would expect to see some renal effect in the hepsin KO mice. Such evidence would make the paper much more exciting.

10.7554/eLife.08887.054

Author response

*We have received reviews from two experts, who found your observations to be a significant advance in our understanding of how uromodulin, in particular, and potentially other ZP proteins are processed. However, Reviewer \#2 and the BRE (Board of Reviewing Editors) member both felt that the paper would be significantly strengthened by the addition of evidence that this function of hepsin is physiologically important. For instance, if your major conclusion is correct, then one would expect to observe some renal effects in the hepsin knockout mice. For instance, do these mice exhibit increased urinary tract infection or other predictable renal phenotypes? If you can include data along these lines and address the other points raised by Reviewer 1, then we would consider a revised version of your paper for publication in* eLife.

Reviewer \#1:

*1) What is known about the longer and more abundant isoform of uromodulin that is secreted by transfected MDCK cells? How has it been secreted if it has not been released from the membrane? Is the sample shown in [Figure 1D](#fig1){ref-type="fig"} from the medium?*

We apologise if this was not clear. The sample in [Figure 1D](#fig1){ref-type="fig"} is indeed from the medium of MDCK cells stably expressing wild-type human uromodulin. Uromodulin is secreted as two isoforms that can be clearly separated by gel electrophoresis after deglycosylation. The short isoform has the same C-terminus and polymerisation properties of urinary protein. Since our main interest was to identify the protease releasing urinary uromodulin, we focused our work on the mechanism generating such short isoform. This was indeed a key step for the final identification of hepsin. We have modified the text in the Results section to clarify this point (subsection "Uromodulin cleavage and polymerisation in MDCK cells is mediated by a serine protease").

We have not investigated the nature of the process generating the long isoform, since we considered this beyond the scope of our study and its physiological relevance is uncertain. The long isoform is likely released from the membrane by a different proteolytic or phospholipase-mediated cleavage.

We carried out mass spectrometry analysis on this isoform revealing a C-terminus (mapped after Asp-N digestion at A611) that is more distal then the physiological one (F587, short isoform) (these data, not included in the manuscript, are shown in [Author response image 1](#fig9){ref-type="fig"}). This is consistent with the slower electrophoretic mobility of this isoform ([Figure 1D](#fig1){ref-type="fig"}).10.7554/eLife.08887.030Author response image 1.Mass spectrometry analysis of the long uromodulin isoform released by MDCK cells.(**A**) Mass spectrometry sequence coverage (42%) of Asp-N-digested human uromodulin (long isoform) from the medium of stably expressing MDCK cells. The analysis was carried out as described in the Methods section of the manuscript. The long isoform was separated in 2D electrophoresis. Matching peptides are shown in red, while the C- terminal peptide is shown in blue. This peptide ends at A611, a distal C-terminal relative to the one identified for the short isoform (F587) that is identical to the one reported for human urinary uromodulin (Santambrogio et al., 2008). (**B**) Representative tandem mass-spectrometry (MS/MS) spectrum confirming the identity of the ^594^DQSRVLNLGPITRKGVQA^611^ C-terminal peptide of the long uromodulin isoform released by MDCK cells and table of fragmented ions.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.030](10.7554/eLife.08887.030)

The presence of a more distal cleavage in MDCK cells is reminiscent of what we identified in the urine of *Hpn* knock-out mice. In vivouromodulin misprocessing at the plasma membrane is only observed in the absence of the physiological protease, i.e. hepsin. In MDCK cells, this prevalent component likely reflects weak expression of hepsin in these cells.

*2) PIC and some of the component proteases certainly reduce the numbers of cells that are expressing uromodulin polymers on their surface. Do the inhibitors affect overall protein expression levels in any way? Could it be that many of the cells are compromised in some fashion?*

We thank the reviewer for this comment. We added this control showing that PIC treatment, that includes the single inhibitors at the same concentration at which they were tested alone, does not affect protein expression and intracellular localisation, as shown by Western blot and immunofluorescence analysis (see new [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}). We conclude that reduction of polymers on the membrane of MDCK cells is not due a reduced amount of protein reaching the plasma membrane, but rather by inhibition of its physiological cleavage (subsection "Uromodulin cleavage and polymerisation in MDCK cells is mediated by a serine protease", third paragraph).

*3) [Figure 3D](#fig3){ref-type="fig"}: It is hard to see that uromodulin polymerization only occurs when wild type proteases are expressed. The images are not that convincing and could be improved. Some confocal images, and possibly some z-projections, may help here.*

We agree with the reviewer that images showing uromodulin polymerisation in HEK293 cells expressing wild-type proteases could be unclear (the reviewer is referring to [Figure 3E](#fig3){ref-type="fig"}). This was partly due to the fact that the original resolution of the pictures was reduced after conversion into pdf format. Nevertheless, as suggested by the reviewer, we have repeated the experiment and acquired high-resolution confocal images of consecutive stacks to generate extended focus images of cell surface and uromodulin polymers.

This analysis contributed to significantly improve the quality of images that are now more clearly showing the presence of polymers only when wild type proteases are expressed (see new [Figure 3A, E](#fig3){ref-type="fig"}).

*4) In the first paragraph of the subsection "Hepsin mediates physiological cleavage and polymerisation of uromodulin in vivo"Line 175: What is meant by the \'mature\' form of uromodulin? And what is the longer isoform shown in [Figure 7A](#fig7){ref-type="fig"} (right)? Is this partially N-deglycosylated? The text reads as if the short uromodulin isoform that is seen in the* Hpn^-/-^*mice is the same as that seen in the wild-type mice, when it is presumably not, as it lacks the physiological C-terminus. Some clarification is required here.*

We thank the reviewer for this comment and agree that this part needed some clarification.

In mice lacking hepsin, uromodulin is misprocessed and its urinary secretion is reduced. Such reduction is not due to changes in gene expression ([Figure 6F](#fig6){ref-type="fig"}) nor to defective protein delivery to the apical membrane. The latter is demonstrated by the fact that the protein accumulating in the kidneys of *Hpn^-/-^* is the "mature" isoform, i.e. it carries post-Golgi type of glycosylation as opposed to the lower band corresponding to the ER precursor (the Endo H sensitivity of the two uromodulin isoforms that are detected in Western blot on mouse kidney lysates was previously shown in Bernascone et al., Hum. Mol. Genet.2010). Importantly, we now added immunofluorescence analysis of uromodulin distribution in mouse kidneys showing that uromodulin signal is clearly enriched on the luminal membrane of TAL segments (new [Figure 6E](#fig6){ref-type="fig"}).

In the absence of hepsin, uromodulin is clearly misprocessed and it is released in the urine as two isoforms that can be separated on gel electrophoresis after deglycosylation. The shorter one has electrophoretic migration similar to the isoform in wild-type urine, though it bears a different, more distal C-terminus ([Figure 7B-D](#fig7){ref-type="fig"}). We have now added mass-spectrometry analysis of the longer isoform, confirming that it is not a product of partial deglycosylation, but rather a product of protein misprocessing with an even more distal C-terminus (new [Figure 7--figure supplement 1](#fig1){ref-type="fig"}).

The part of the Results section describing these findings ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}) has been rephrased and integrated to improve its clarity (subsection "Hepsin mediates physiological cleavage and polymerisation of uromodulin in vivo", first two paragraphs).

*5) Is prostasin expressed on the surface of the TAL in mouse kidney and does it co-localize with uromodulin?*

As suggested by the reviewer, we checked expression of prostasin in the TAL segment of mouse kidney by Real-time qRT-PCR on RNA from microdissected nephron segments and immunofluorescence. Prostasin is weakly expressed in the TAL (while for instance it is highly expressed in proximal tubules) where it is mostly detected on the apical membrane of epithelial cells, as shown by co-localisation with uromodulin (see new [Figure 7--figure supplement 2A, B](#fig7s2){ref-type="fig"} and corresponding description in the subsection "Hepsin mediates physiological cleavage and polymerisation of uromodulin in vivo", last paragraph). These results are consistent with expression data derived from available transcriptomes ([Figure 3C](#fig3){ref-type="fig"}) and with localisation of transfected prostasin on the apical membrane of polarised MDCK cells ([Figure 5A](#fig5){ref-type="fig"}).

Despite co-localisation of prostasin and uromodulin in TAL cells, this protease is not involved in physiological processing of uromodulin, as clearly demonstrated by the analysis of uromodulin processing in the specific knock-out mice ([Figure 7--figure supplement 2C-F](#fig7s2){ref-type="fig"}).

*6) It is certainly intriguing that the phenotype of the tectorial membrane in the inner ear of* Hpn^-/-^*mice is morphologically very similar (at the light microscope level) to that seen in mice that are heterozygous for deafness-causing, semi-dominant missense mutations in the ZP domain of Tecta. Mutations in ZP2 corresponding to two of these Tecta ZP domain mutations (C1837G and Y1870C) have been shown to prevent the secretion of ZP2 in vitro (Jovine et al., 2002).*

We thank the reviewer for this interesting comment. The morphological similarity of structural abnormalities of tectorial membrane in *Hpn* knock-out mice and in mouse models carrying deafness-causing *Tecta* mutations (Legan et al., 2005, 2014) indeed suggests the intriguing possibility that hepsin could play a role in tectorin processing. One could hypothesise that structural defects of the tectorial membrane in these models are due to reduced/altered secretion of tectorins, either because of protein trafficking defect (*Tecta* semi-dominant mutations) or because of misprocessing at the plasma membrane (*Hpn* loss-of-function mutation). We rephrased this part of the Discussion section and added citation of these papers (last paragraph).

Reviewer \#2:

*The biochemistry and discovery of the protease responsible for cleaving uromodulin are compelling. However, it is disappointing that there wasn\'t any evidence to suggest hepsin is physiologically important. Based on their data showing reduced secretion of uromodulin -- one would expect to see some renal effect in the hepsin KO mice. Such evidence would make the paper much more exciting.*

We thank the reviewer for considering the experimental data presented in the manuscript a compelling demonstration that hepsin is the protease responsible for uromodulin physiological cleavage. Considering that this work spans extensive *in vitro* and *in vivo* analyses, we believe that this conclusion is *per se* physiologically relevant, as it identifies the first *in vivo* substrate of hepsin and the first protease involved in the extracellular release of a ZP domain protein.

We understand the point raised by the reviewer (also shared by the BRE). If the lack of physiological processing of uromodulin is associated to a renal phenotype is indeed an interesting question, and we have been extensively thinking of ways to address it.

However, we feel that experiments along this line in *Hpn*^-/-^ mice would likely be inconclusive for the following reasons:

1\) Currently uromodulin biological functions are not clearly determined. The protective role of urinary uromodulin against UTI and nephrocalcinosis has been established by studies on *Umod* KO mice, challenged by transuretheral bacteria injection (Bates et al., Kidney Int 2004; Mo et al., Am J Physiol Ren Physiol2004) or by ethylene glycol diet (Mo et al., Kidney Int2004). Spontaneous nephrocalcinosis was also reported, with frequency increasing with age (Mo et al., Am J Physiol Ren Physiol 2007; Liu et al., Am J Physiol Ren Physiol 2010). Although with some contrasting results, possibly due to different genetic background, baseline renal function parameters in *Umod* mice are not substantially affected, with the possible exception of reduced creatinine clearance, to date unexplained (Bachmann et al., Am J Physiol Ren Physiol 2005; Graham et al., Hypertension 2013).

Predictable renal phenotypes in *Hpn* KO mice would hence be based on uromodulin functions as deduced from *Umod* KO studies. However, *Hpn* KO mice show misprocessing and reduction of 60-70% of urinary uromodulin levels that may not mimic complete absence of urinary protein and hence lead to the same phenotype. It is of note that phenotype in *Umod*^+/-^ mice (possibly closer to *Hpn* KO mice in terms of levels of uromodulin urinary) has not been reported, with the exception of one study showing increased frequency of nephrocalcinosis in aged mice (Liu et al., Am J Physiol Ren Physiol 2010).

2\) The interpretation of any experiment assessing renal phenotype(s) in *Hpn* KO mice would be undermined by the fact that any evidence could not be conclusively linked to reduced/misprocessed uromodulin, not knowing how many other substrates hepsin has in the kidney or in the urinary tract. The fact that this protease is expressed in other nephron segments seems to argue in favour of possible additional functions. Moreover, renal parameters may also be reflecting the consequences of the lack of hepsin in other organs. To properly study the renal consequences of the lack of hepsin-mediated processing of uromodulin we feel that a more appropriate and rigorous genetic approach would be needed, as for instance the generation of a knock-in mouse carrying mutation of uromodulin on the hepsin cleavage site. This is indeed a line of investigation that we plan to follow in the next years.

Although we believe that these considerations would undermine the significance of any study in *Hpn*^-/-^ mice, we anyway made considerable efforts to investigate possible renal phenotype in these mice.

We first evaluated renal parameters that were reported to be altered in *Umod* KO mice. Baseline levels of serum creatinine and blood urea nitrogen are similar in *Hpn* KO mice and wild-type littermates, suggesting normal renal function (see Discussion section, first paragraph). Also, genes shown to be differentially expressed in the kidneys of *Umod* KO mice (i.e. *Ptgs2*, *Slc12a3*, *Kcnj1*; Bachmann et al., Am J Physiol Ren Physiol 2005) are expressed at levels comparable with wild-type littermates in *Hpn* KO mice (see [Author response image 2](#fig10){ref-type="fig"}).10.7554/eLife.08887.031Author response image 2.Expression level of renal genes in *Hpn*~-/-~ mice.Quantification by Real-time qPCR of the mRNA levels of cyclooxygenase 2 (Cox2) (*Ptgs2*), sodium-chloride co-transporter (NCC) (*Slc12a3*) and the renal outer medullary potassium channel (ROMK) (*Kcjn1*) in kidneys of *Hpn~-/-~*mice relative to age- and sex- matched wild-type controls (n = 3/group). Bars indicate average ratio ± s.e.m.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.031](10.7554/eLife.08887.031)

In the due time it was not possible to carry out thorough *in vivo* experiments to assess for instance if *Hpn* KO mice develop a phenotype upon different challenges (e.g. transurethral bacteria injection, aging-associated nephrocalcinosis, etc.).

We envisaged an alternative strategy by testing *ex vivo* anti-bacterial properties of urines from *Hpn* KO mice. This approach stems from the evidence that uromodulin can bind type 1-fimbriated uropathogenic *E. coli* through its high-mannose moieties (Pak et al., J Biol Chem 2001). Thanks to this property, it is thought that urinary uromodulin can compete with binding of type 1-fimbriated *E. coli* to high-mannose glycans of the urothelial membrane proteins uroplakins (Wu et al., PNAS 1996), thereby acting as a major urinary defence factor against bacterial infections. Although we still lack conclusive evidence of such a role of uromodulin from human studies, increased colonisation of the urinary bladder and more persistent bacteriuria in *Umod* KO mice upon bacteria injection (Bates et al., Kidney Int 2004; Mo et al., Am J Physiol Ren Physiol 2004) support this hypothesis.

We reasoned that testing the ability of mouse urines (or purified urinary proteins) to inhibit mannose-dependent adhesion of type 1-fimbriated *E. coli* could mimic the *in vivo* interactions expected to occur in experimental models of urinary tract infection.

For these experiments we employed 3 different assays testing *E. coli* adhesion: 1) agglutination of rat erythrocytes (Wu et al., PNAS 1996); 2) yeast agglutination (Mirelman et al., J Clin Microbiol 1980; Wang et al., BMC Microbiol 2012); 3) adhesion to the surface of urothelial cells (Orskov et al., Infect Immun1980; Martinez et al., EMBO J 2000). Haemagglutination and yeast agglutination assay were successfully set up to screen uropathogenic bacteria clinical isolates (in collaboration with Dr. Nicasio Mancini, Microbiology and Virology Laboratory, San Raffaele Hospital). Out of 16 *E. coli* isolates, we eventually selected 3 that clearly induced haemagglutination and mannose-sensitive yeast agglutination, confirming their phenotype as type 1-fimbriated (see [Author response image 3](#fig11){ref-type="fig"}). The same isolates could also bind to the surface of urothelial cells in a mannose-sensitive manner.10.7554/eLife.08887.032Author response image 3.Yeast agglutination assays on uropathogentic *E. coli* clinical isolates.Representative images of yeast agglutination assay. The assay was performed incubating 10 µl of previously identified bacteria isolates (haemagglutination-positive isolates \#9, 12, 10), grown in static condition (final concentration 2x10^9^ cells/ml), with 10 µl of *S. cerevisiae* yeast strain W303 Mata (final concentration of 10^9^ cells/ml). The appearance of white aggregates (arrows) indicates agglutination. UTI isolates were pre-incubated with D- mannose at a final concentration of 2.5% in order to identify mannose-sensitive agglutination, indicative of type 1-fimbriated phenotype. The assay was carried out in 3 replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.08887.032](10.7554/eLife.08887.032)

Unfortunately, these assays gave contrasting and inconclusive results when we employed human urine-purified uromodulin (tested range 0.1-1 µg/µl), mouse urinary proteins (0.2-0.7 µg/µl) or mouse urine (1:1-1:20 dilutions). A partial effect of purified uromodulin on yeast agglutination and bacteria adhesion to urothelial cells could be observed, while mouse urine and mouse urinary proteins had no effect in any assay. We observed some difference between wild-type and *Hpn*^-/-^ urinary protein samples in their inhibitory effect on bacterial adhesion to urothelial cells in a single experiment, but this result could not be convincingly reproduced.

Overall, we believe that such experiments would require extensive set up and analysis to be optimised for mouse urinary samples. As for experiments *in vivo* we feel that this would be well beyond the scope of the current work.

Nonetheless, we wish to point out that, for the considerations stated above, experiments in the *Hpn*^-/-^ model would eventually lead to results that could not be conclusively interpreted.
